Carmel Capital Partners’s UroGen Pharma URGN Stock Holding History

Carmel Capital Partners’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-259	Closed	-$3.63K	–	665
2023 Q3	$3.63K	Buy	259 +59	+30%	+$947	﹤0.01%	582
2023 Q2	$2.07K	Buy	+200	New	+$2.21K	﹤0.01%	362

Other funds holding URGN

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Carmel Capital Partners's URGN Position: Q4 2023 in Review

Carmel Capital Partners sold out of UroGen Pharma (URGN) in Q4 2023, closing a stake of 259 shares — an estimated $3.63K sold.

Carmel Capital Partners first reported a position in URGN in Q2 2023 and held it in 2 quarters. The position peaked at $3.63K in Q3 2023. 105 funds tracked by Wall St. Rank hold URGN as of Q4 2023.

Carmel Capital Partners reported no remaining UroGen Pharma position as of Q4 2023 after selling out during the quarter.
Carmel Capital Partners sold 259 UroGen Pharma shares in Q4 2023, an estimated $3.63K.
Carmel Capital Partners first reported a position in UroGen Pharma in Q2 2023 and held it in 2 quarters.
Carmel Capital Partners's UroGen Pharma position peaked at $3.63K in Q3 2023.
105 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2023.

Based on Carmel Capital Partners's 13F filing for Q4 2023, filed 1 Feb 2024.